ObjectivesThis study was conducted to determine whether establishment of the pan-Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug listing decisions across Canada.Analysis and resultsThis study included drug indications that received a Common Drug Review or pan-Canadian Oncology Drug Review listing recommendation within 3 years before (‘pre-PCPA era’ group; n=79) and 3 years after (‘PCPA era’ group; n=91) the pCPA was established in August 2010. At the time of this study (30 April 2014), nine pCPA-participating jurisdictions had listed 35–59% of drug indications in the pre-pCPA era group and a nearly identical range, 36–59%, in the pCPA era group. Within the pCPA-era group, 31 drug indications (34%) had completed pCPA negotiations (‘pCPA negotiation’ subgroup); the jurisdictions had listed 39–77% of these drug indications. Comparison of the pCPA era group to the pre-pCPA era group indicated that the proportion listed did not change significantly in any jurisdiction, and time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba, and Ontario. When the pCPA negotiation subgroup was compared to the pre-pCPA era group, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador, and time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario. A sensitivity analysis suggested more favourable results regarding the pCPA's impact.ConclusionsWhile the pCPA might have had a varied effect on time-to-listing, this study's primary analysis did not observe a significant impact on the overall proportion of new drug indications listed across jurisdictions. This may be due to the fact that, at the time of this study, only a limited number of drug indications had completed pCPA negotiations. This study provides a framework for future evaluations of the pCPA's impact as it continues to evolve.

Treatment of advanced NSCLC (aNSCLC) is rapidly evolving, as new targeted and immuno-oncology (I-O) treatments become available. The iTEN model was developed to predict the cost and survival benefits of changing aNSCLC treatment patterns from a Canadian healthcare system perspective. This report describes iTEN model development and validation. Materials & methods: A discrete event patient simulation of aNSCLC was developed. A modified Delphi process using Canadian clinical experts informed the development of treatment sequences that included commonly used, Health Canada approved treatments of aNSCLC. Treatment efficacy and the timing of progression and death were estimated from published Kaplan-Meier progression free and overall survival data. Costs (2018 CDN$) included were: drug acquisition and administration, imaging, monitoring, adverse events, physician visits, best supportive care, and end-of-life. Results and conclusion: Clinical validity of the iTEN model was assessed by comparing model survival predictions to published real-world evidence (RWE). Four RWE studies that reported the overall survival of patients treated with a broad sampling of common aNSCLC treatment patterns were used for validation. The validation coefficient of determination was R 2 = 0.95, with the model generally producing estimates that were neither optimistic nor conservative. The model estimated that current Canadian practice patterns yield a median survival of almost 13 months, a five-year survival rate of 3% and a lifetime per-treated-patient cost of $110,806. Cost and survival estimates are presented and were found to vary by aNSCLC subtype. In conclusion, the iTEN model is a reliable tool for forecasting the impact on cost and survival of new treatments for aNSCLC. [1]. It is the leading cause of cancer-related mortality in Canada, accounting for approximately 26% of all cancer-related deaths [1]. Nonsmall cell lung cancer (NSCLC) is the most common form, representing approximately 80-85% of all lung cancers [2]. Approximately 50% of

Ginger (Zingiber officinale) is one of the important and widely used spices throughout the world in fresh and dried forms. The study on quality characterization and essential oil profiling of 13 ginger genotypes was conducted at ICAR-Indian Institute of Spices Research, Kozhikode, Kerala, during 2019-2020. The genotypes included eight promising exotic accessions (Acc. 393, Acc. 607, Acc. 736, Acc. 833, Acc. 869, Acc. 872, Acc. 873 and Acc. 874), four popular cultivars (Nadan, Himachal, Maran, Rio-de-Janeiro) and a released variety IISR Varada. Significant differences among the genotypes were recorded for various quality parameters such as oleoresin, essential oil and crude fibre content. Among the exotic genotypes, Acc. 869 recorded the highest essential oil content (2.44%), followed by Acc. 393 (2.42%), Acc. 833 and Acc. 873 (2.10%). The accessions, Acc. 869, Acc. 874, Acc. 873 and Acc. 393 recorded higher oleoresin content of 5.88 per cent, 5.63 per cent, 5.34 per cent and 5.28 per cent, respectively. Considering essential oil and oleoresin contents, the exotic accessions, Acc. 873, Acc. 393 and Acc. 869 were identified as promising genotypes. Among the other genotypes, Rio-de-Janeiro recorded the highest essential oil (2.76%) and oleoresin content (6.69%). The exotic genotypes, viz., Acc. 607, Acc. 736 and Acc. 393 recorded crude fibre content of less than 5 per cent whereas, Acc. 869 recorded the maximum of 7.85 per cent. Fifty compounds were identified through essential oil profiling, and the major classes were sesquiterpene hydrocarbons followed by monoterpene hydrocarbons. The major compound identified was α-zingiberene and was highest in Acc. 393 (30.49%), followed by Maran (30.32%).

The study suggests that the development of metastasis in Dukes B tumours may be predictable based on the miRNA expression of miR-15b and miR-135b. This requires further study on a much larger cohort.

No abstract